For instance, 78% of EscharEx patients achieved wound bed preparation, versus 38% of SANTYL, with a 33% wound closure rates compared to SANTYL’s 25%. Given these results, EscharEx has a strong ...

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® “These new findings are consistent with my ...

The analysis, derived from the company’s Phase II ChronEx trial data, suggests that EscharEx achieved faster and more complete debridement of VLUs compared to patients treated with SANTYL. Complete ...

The analysis compares the efficacy and safety of its product EscharEx® against SANTYL®, the only FDA-cleared enzymatic debridement agent. Key findings include that EscharEx achieved complete ...

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® “These new findings are ...

The analysis, derived from the company’s Phase II ChronEx trial data, suggests that EscharEx achieved faster and more complete debridement of VLUs compared to patients treated with SANTYL.

“These new findings are consistent with my prior experience using EscharEx in clinical trials and SANTYL in clinical practice,” said Dr. Cyaandi Dove, DPM, of the University of Texas Health ...

The analysis is based on data from the Company’s Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx ® compared with collagenase ...

(MENAFN- GlobeNewsWire - Nasdaq) Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL ...

There was also a slow quarter for SANTYL after strong finish to Q4, again reflecting wholesaler stocking patterns. As a reminder, we expect AWB growth for full year to be in the low single digits.